الفهرس | Only 14 pages are availabe for public view |
Abstract Electronic databases, clinical trials registries and other sources were searched. No restrictions on language or publication status were set. All clinical trials were included. The outcomes of interest were tooth survival after root canal treatment, radiographic healing, post-operative pain, flare-up incidence, swelling incidence, analgesic intake, TTP, clinical healing, tooth mobility, sinus tract, antibacterial effectiveness and endotoxins{u2019} level. Risk of bias assessment was done by RoB 2.0 tool for RCTs and QRCTs and by D&B tool for non-RCTs. Meta-analysis was carried out for studies with similar comparisons, outcome measures and time points using the fixed effect model.Thirty-eight studies were included in this review; 26 studies were RCTs, two studies were QRCTs and 10 studies were non-RCTs. CH reduced the risk of post-operative pain compared to No ICM over three days (RR pooled 0.89, 95% CI 0.83 to 0.95, I2 63%, 2 studies, 350 teeth).There was no evidence of difference between CH and Cs/Ab in terms of post-operative pain over three days.There was no evidence of difference between CH and CH/Iodoform regarding short-term clinical healing after one week of application. CH reduced the risk of positive bacterial cultures compared to CHX after two weeks of application |